YM-529
YM-529 物理性質
- 比重(密度) :
- 1.97±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- under inert gas (nitrogen or Argon) at 2-8°C
- 溶解性:
- Aqueous Base (Slightly), Methanol (Slightly)
- 外見 :
- Solid
- 酸解離定数(Pka):
- 1.48±0.10(Predicted)
- 色:
- White to Off-White
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
|
| 注意書き |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
| P305+P351+P338 |
眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
YM-529 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
YM-529 化学特性,用途語,生産方法
説明
Minodronic acid hydrate, a third-generation bisphosphonate, was
approved and launched in Japan for the oral treatment of
osteoporosis. Osteoporosis is a skeletal disorder characterized by low bone mass and structural deterioration of bone tissue resulting in bone
fragility and increased susceptibility to fractures, particularly of the hip,
spine, and wrist. It is the most common type of metabolic bone disease
and a major health concern affecting 200 million women worldwide.
Minodronic acid is the newest nitrogen-containing bisphosphonate to reach the market. In vitro, it inhibits
recombinant human FPP synthase activity with similar potency as zoledronic acid (IC
50 = 3 nM for both agents).
The most common adverse events associated with minodronic acid included stomach and abdominal discomfort, abdominal pain, decrease in blood calcium level, and gastritis. The chemical synthesis of minodronic acid starts with a condensation reaction of 2-aminopyridine with ethyl 4-bromo-3-oxobutyrate by means of sodium bicarbonate to produce 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid ethyl ester, which is hydrolyzed to the corresponding carboxylic acid with potassium hydroxide. Treatment of the carboxylic acid intermediate with phosphorus acid and phosphorus trichloride followed by hydrolysis with hydrochloric acid gives minodronic acid.
使用
Minodronic acid is developed for osteoporosis treatment.
YM-529 上流と下流の製品情報
原材料
準備製品
YM-529 生産企業
Global( 146)Suppliers
180064-38-4(YM-529)キーワード:
- 180064-38-4
- PHOSPHONIC ACID, (1-HYDROXY-2-IMIDAZO(1,2-A)PYRIDIN-3-YLETHYLIDENE)BIS-
- 1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bis(phosphonic acid)
- (1-Hydroxy-2-imidazo[1,2-A]pyridin-3-yl-1-ethyl)-1,1-bisphos phonate
- Nsc725590
- Bonoteo
- BPH 261
- ONO 5920
- Recalbon
- (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid
- Phosphonic acid,P,P'-(1-hydroxy-2-iMidazo[1,2-a]pyridin-3-ylethylidene)bis-
- Minodronic acid (anhydrous)
- (127657-42-5) minodronic acid
- 1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)-1,1-ethanediyl]bis(phosphonic acid)
- Minodronicaci
- PHOSPHONIC ACID, (1-HYDROXY-2-IMIDAZO(1,2-A)PYRIDIN-3-YLETHYLIDENE)BIS- ISO 9001：2015 REACH
- Minodronic Acid
- Mino phosphate
- Phosphonicacid,(1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-|||ONO-5920|||YM-529
- YM-529
- ミノドロネート
- ミノドロン酸
- (1-ヒドロキシ-2-{イミダゾ[1,2-a]ピリジン-3-イル}-1-ホスホノエチル)ホスホン酸
- 1-ヒドロキシ-2-(イミダゾ[1,2-a]ピリジン-3-イル)エチリデンビスホスホン酸
- ミノドロナート
- [1-ヒドロキシ-2-(イミダゾ[1,2-a]ピリジン-3-イル)エチリデン]ビスホスホン酸
- 1-ヒドロキシ-2-(イミダゾ[1,2-a]ピリジン-3-イル)エタン-1,1-ジイルビス(ホスホン酸)